Autotaxin signaling facilitates β cell dedifferentiation and dysfunction induced by Sirtuin 3 deficiency

Area of Science:

• Endocrinology
• Molecular Biology
• Metabolic Diseases

Background:

• Pancreatic beta cell dedifferentiation is implicated in type 2 diabetes (T2D) pathogenesis.
• Sirtuin 3 (Sirt3) deficiency in beta cells impairs glucose homeostasis and insulin secretion under high-fat diet (HFD) conditions.
• Sirt3-deficient islets exhibit increased expression of autotaxin (ATX), an enzyme producing lysophosphatidic acid (LPA).

Purpose of the Study:

• To investigate the role of the ATX/LPA pathway in beta cell dedifferentiation in Sirt3-deficient models.
• To elucidate the mechanisms by which LPA affects beta cell function and dedifferentiation.
• To evaluate the therapeutic potential of targeting the ATX/LPA pathway in T2D.

Main Methods:

• Applied LPA and lysophosphatidylcholine (LPC) to MIN6 cells and mouse islets with altered Sirt3 expression.
• Utilized beta cell-specific adeno-associated virus (AAV) to inhibit ATX in Sirt3-deficient mice on HFD.
• Analyzed beta cell dedifferentiation, insulin secretion, and signaling pathways (JNK/p38 MAPK).

Main Results:

• LPA induced reversible beta cell dedifferentiation and reduced insulin secretion in vitro and in islets.
• LPA triggered JNK/p38 MAPK phosphorylation, contributing to beta cell dedifferentiation.
• Inhibition of ATX in vivo improved insulin secretion and reduced beta cell dedifferentiation in HFD-fed Sirt3-deficient mice.

Conclusions:

• Sirt3 protects beta cells from dedifferentiation by suppressing ATX expression and subsequent LPA production.
• The ATX/LPA pathway is a key mediator of Sirt3's protective effects against glucolipotoxicity-induced beta cell dysfunction.
• Targeting the ATX/LPA pathway represents a potential therapeutic strategy for T2D.